Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#117 of 388

Ben Hendrix

RBC Capital · Equity Research Analyst
EstablishedRating since 2022No new ratings since Jul 2025

Analyst rating accuracy & track record

Ben Hendrix is an equity research analyst at RBC Capital. Quantellect has scored 57 of their stock calls across 14 companies. Their picks beat their sector 44% of the time over the next 12 months, and their price targets were reached 48% of the time within a year.

Win % vs sector
44%
PT Hit % (12mo)
48%
Avg sector-excess
−1.1%
Scored calls
57
Tickers
14
Tier
Established

Track record

Quantellect has scored 57 of Ben Hendrix's stock calls across 14 companies, dating back to 2022. Their rated stocks beat their own sector 44% of the time over the next 12 months. On a typical call, a Hendrix pick returned −1.1% more than its sector over the following year.

Of the scored calls, 57 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
BKDBrookdale Senior Living Inc
Buy$9.00Jul 2025+76.9%Hit
CHEChemed Corp
Buy$640.00Jun 2025−20.8%Miss
ARDTArdent Health Partners, Inc.
Buy$21.00May 2025−45.4%Miss
AHCOAdapthealth Corp
Buy$13.00May 2025+21.7%Hit
BKDBrookdale Senior Living Inc
Buy$9.00May 2025+79.7%Hit
SEMSelect Medical Holdings
Buy$19.00May 2025+4.2%Miss
EHCEncompass Health Corp
Buy$125.00Apr 2025−16.8%Hit
CHEChemed Corp
Buy$674.00Apr 2025−31.5%Miss
BKDBrookdale Senior Living Inc
Buy$8.00Apr 2025+126.1%Hit
SGRYSurgery Partners Inc
Buy$35.00Mar 2025−52.7%Miss
CHEChemed Corp
Buy$667.00Mar 2025−38.9%Miss
ARDTArdent Health Partners, Inc.
Buy$21.00Mar 2025−43.8%Miss
AHCOAdapthealth Corp
Buy$14.00Feb 2025−26.9%Miss
SEMSelect Medical Holdings
Buy$23.00Feb 2025−29.2%Miss
BKDBrookdale Senior Living Inc
Buy$8.00Feb 2025+166.9%Hit
EHCEncompass Health Corp
Buy$110.00Feb 2025+7.4%Hit
CONConcentra Group Holdings Parent, Inc.
Buy$30.00Jan 2025−18.4%Miss
BKDBrookdale Senior Living Inc
Buy$8.00Dec 2024+96.7%Hit
SGRYSurgery Partners Inc
Buy$35.00Nov 2024−41.5%Miss
AHCOAdapthealth Corp
Buy$11.00Nov 2024−14.9%Hit
ADUSAddus HomeCare Corporation
Buy$136.00Nov 2024−17.9%Hit
ADUSAddus HomeCare Corporation
Buy$136.00Nov 2024−11.2%Hit
CHEChemed Corp
Buy$633.00Nov 2024−20.0%Miss
SEMSelect Medical Holdings
Buy$47.00Nov 2024−32.1%Miss
CONConcentra Group Holdings Parent, Inc.
Buy$30.00Nov 2024+0.1%Miss
EHCEncompass Health Corp
Buy$110.00Oct 2024+18.2%Hit
ENSGThe Ensign Group Inc
Buy$172.00Oct 2024+18.8%Hit
PNTGPennant Group Inc
Buy$38.00Oct 2024−26.0%Miss
ENSGThe Ensign Group Inc
Buy$167.00Oct 2024+25.5%Hit
BKDBrookdale Senior Living Inc
Buy$9.00Oct 2024+56.8%Hit
EHCEncompass Health Corp
Buy$105.00Sep 2024+42.7%Hit
CICigna Corp
Buy$384.00Sep 2024−4.6%Miss
CONConcentra Group Holdings Parent, Inc.
Buy$33.00Aug 2024+9.5%Miss
AHCOAdapthealth Corp
Buy$13.00Aug 2024+10.1%Miss
CYHCommunity Health Systems Inc
Buy$6.00Aug 2024−37.2%Hit
BKDBrookdale Senior Living Inc
Buy$9.00Aug 2024+15.2%Miss
BKDBrookdale Senior Living Inc
Buy$9.00Jul 2024+13.4%Miss
CHEChemed Corp
Buy$697.00May 2024+11.4%Miss
PACSPACS Group, Inc.
Buy$32.00May 2024−53.1%Hit
PACSPACS Group, Inc.
Buy$30.00May 2024−56.3%Hit
SEMSelect Medical Holdings
Buy$40.00May 2024−12.6%Hit
BKDBrookdale Senior Living Inc
Buy$9.00Apr 2024−11.1%Miss
AHCOAdapthealth Corp
Buy$13.00Mar 2024−4.1%Miss
CHEChemed Corp
Buy$712.00Mar 2024−11.2%Miss
ENSGThe Ensign Group Inc
Buy$133.00Feb 2024+22.6%Hit
BKDBrookdale Senior Living Inc
Buy$9.00Nov 2023−18.2%Miss
AHCOAdapthealth Corp
Buy$13.00Nov 2023+23.7%Miss
CHEChemed Corp
Buy$604.00Oct 2023−12.3%Hit
CHEChemed Corp
Buy$576.00Jul 2023−5.4%Hit
SEMSelect Medical Holdings
Buy$38.00Jul 2023+13.5%Hit
Go to

Ben Hendrix: analyst track record FAQ

Is Ben Hendrix a good stock analyst?

Yes, by track record. Ben Hendrix ranks number 117 of 388 of the analysts Quantellect scores, with a Q Score of 47 out of 100. Past results do not guarantee future ones.

What is Ben Hendrix's win rate?

Ben Hendrix's win rate is 44%. Across 57 scored calls, their rated stocks beat their sector 44% of the time over the next 12 months. On a typical call they returned −1.1% more than the sector.

What stocks and sectors does Ben Hendrix cover?

Ben Hendrix covers 14 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Ben Hendrix's price targets accurate?

Ben Hendrix's price targets are reached within 12 months 48% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Ben Hendrix's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Ben Hendrix rank among Wall Street analysts?

Ben Hendrix ranks number 117 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.